Developing a stable specialty polymer for use in energy applications for Kraton
Learn how Syngene partnered with a leading producer of specialty polymers to develop a novel polymer for use in energy applications.
Overcoming analytical challenges with chemical derivatization in LD-MS/MS
Learn about the challenges in chemical derivatization and utilizing LC-MS/MS to detect and quantify trace compounds in complex molecules for supporting bioanalytical studies.
Direct scale up from clone to 2K GMP batches
Learn how Syngene scientists scaled up a clone directly from lab scale to clinical scale and enabled clinical batch manufacturing of the product with an improved titer of >5g/L.
Comprehensive preclinical evaluation of bile acid modulators for paediatric liver disease
Learn how Syngene executed complex preclinical studies, consolidating data across pharmacokinetics, biomarker modulation, and gene expression analysis, and provided comprehensive insights for the client’s development decision on bile acid modulators for paediatric liver disease.
Enabling high product quality, and yield through process optimization for biologics
Learn how Syngene’s expertise in process optimization enabled a biopharma company to achieve high product quality and yield for its PPQ batches, including enabling appropriate scale-up to commercial.
Long acting injectables: Accelerating the path to patient wellbeing
Learn about the various challenges in developing LAIs and the technologies and techniques being used by Syngene to help clients use this transformative drug delivery system to treat chronic diseases.
Developing a green synthesis process for a growth promoter drug for animals
Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.
Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process
Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.
IND-enabling safety tox studies for FDA submission in just 9 months
Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.